Copayment

The Assistance Fund Opens New Assistance Program for Pulmonary Hypertension Medication Copays

Retrieved on: 
Tuesday, January 29, 2019
Health, Pharmaceutical, General Health, Hypertension, Health insurance, RTT, Health, Aging-associated diseases, Copayment, Healthcare in the United States, Medicine, Pulmonary hypertension, Articles

The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the opening of a new Copay Assistance Program for Pulmonary Hypertension.

Key Points: 
  • The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the opening of a new Copay Assistance Program for Pulmonary Hypertension.
  • The program provides eligible patients with financial assistance for copayments for FDA-approved medications related to their condition.
  • Individuals with Pulmonary Hypertension have increased pressure in the arteries that carry blood from the heart to the lungs.
  • At the Assistance Fund, we know that getting the best possible treatment for Pulmonary Hypertension is absolutely key, but high copays can make recommended treatments prohibitively costly to the patient.

Financial Assistance from The Assistance Fund Now Available for Eligible Individuals with Lambert-Eaton Myasthenic Syndrome

Retrieved on: 
Monday, January 28, 2019
Health, Hospitals, Philanthropy, Other Philanthropy, General Health, Managed care, Healthcare in the United States, Health, Articles, Copayment, Health insurance, Out-of-pocket expense, Co-insurance, High-deductible health plan

The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new financial assistance program for individuals living with Lambert-Eaton Myasthenic Syndrome, often referred to as LEMS.

Key Points: 
  • The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new financial assistance program for individuals living with Lambert-Eaton Myasthenic Syndrome, often referred to as LEMS.
  • The program is designed to help eligible individuals living with LEMS pay for out-of-pocket medical expenses resulting from the disorder.
  • The Assistance Fund is an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles and other health-related expenses.
  • The Assistance Fund currently manages more than 50 programs each of which covers the FDA-approved medications that treat a specific disease.

Lysosomal Acid Lipase Deficiency Financial Assistance Program Launched by The Assistance Fund

Retrieved on: 
Friday, January 25, 2019
Women, Practice Management, Health, Biotechnology, Pharmaceutical, Philanthropy, Consumer, Foundation, MEN, Enzymes, Branches of biology, Proteins, Lysosomal lipase, Lipase, Copayment, Lysosome, Assistance, Acid lipase disease

The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new financial assistance program for individuals living with Lysosomal Acid Lipase Deficiency.

Key Points: 
  • The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new financial assistance program for individuals living with Lysosomal Acid Lipase Deficiency.
  • An ultra-rare, chronic, progressive disorder, Lysosomal Acid Lipase Deficiency (LAL-D) is caused by abnormalities in the LIPA gene, which is responsible for the bodys ability to produce the lysosomal acid lipase (LAL) enzyme.
  • The Assistance Fund is an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles and other health-related expenses.
  • The Assistance Fund currently manages more than 50 programs each of which covers the FDA-approved medications that treat a specific disease.

Eligible Individuals with Hypophosphatasia to Receive Financial Assistance from The Assistance Fund

Retrieved on: 
Tuesday, January 22, 2019
Health, Genetics, Hospitals, Philanthropy, Other Philanthropy, General Health, Managed care, Health, Healthcare in the United States, Copayment, Health insurance, Assistance, Out-of-pocket expense, Healthcare reform in the United States, High-deductible health plan, Prescription drug

The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the opening of a new financial assistance program for Hypophosphatasia.

Key Points: 
  • The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the opening of a new financial assistance program for Hypophosphatasia.
  • We are honored to now be another pillar of support for those living with this disorder through our financial assistance program.
  • The Assistance Fund is an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles and other health-related expenses.
  • The Assistance Fund currently manages more than 50 programs each of which covers the FDA-approved medications that treat a specific disease.

The Assistance Fund Announces New Financial Assistance Program for Individuals with Paroxysmal Nocturnal Hemoglobinuria

Retrieved on: 
Friday, January 18, 2019
Health, Philanthropy, Professional services, Finance, Other Philanthropy, Foundation, General Health, Acquired hemolytic anemia, Paroxysmal nocturnal hemoglobinuria, PNH, Copayment, Assistance, Health, Healthcare reform in the United States

The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high out-of-pocket medical costs, today announced the launch of a new financial assistance program for individuals living with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Key Points: 
  • The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high out-of-pocket medical costs, today announced the launch of a new financial assistance program for individuals living with Paroxysmal Nocturnal Hemoglobinuria (PNH).
  • At The Assistance Fund, it is important for us to recognize and support those living with rare and ultra-rare conditions like PNH.
  • The Assistance Fund is an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles and other health-related expenses.
  • The Assistance Fund currently manages more than 50 programs each of which covers the FDA-approved medications that treat a specific disease.

New Copay Assistance Program for Individuals Living with Chronic Lymphocytic Leukemia Established by The Assistance Fund

Retrieved on: 
Monday, January 14, 2019
Stem cells, Health, Oncology, Philanthropy, Professional services, Insurance, Other Philanthropy, General Health, RTT, Leukemia, Copayment, CLL, Health, Medicine, Breakthrough therapy, Tyrosine kinase inhibitors, Chronic lymphocytic leukemia

The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new copay assistance program for eligible individuals living with Chronic Lymphocytic Leukemia (CLL).

Key Points: 
  • The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new copay assistance program for eligible individuals living with Chronic Lymphocytic Leukemia (CLL).
  • We are proud to share the news of this recent program launch as it will help to alleviate some of the financial stress for individuals living with this disease.
  • A list of all the programs available at The Assistance Fund can be found on the website tafcares.org.
  • The Assistance Fund currently manages more than 50 programs each of which covers the FDA-approved medications that treat a specific disease.

Breast Cancer Copay Assistance Program Launched by The Assistance Fund

Retrieved on: 
Tuesday, January 8, 2019
Health, Oncology, Philanthropy, Professional services, Finance, Insurance, Other Philanthropy, General Health, Health insurance, Healthcare in the United States, Health, Copayment, Co-insurance, Healthcare reform in the United States

The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the opening of a new copay assistance program designed to provide financial assistance to eligible individuals living with Breast Cancer.

Key Points: 
  • The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the opening of a new copay assistance program designed to provide financial assistance to eligible individuals living with Breast Cancer.
  • Breast Cancer is caused by uncontrolled cell growth in the breast, which can develop into tumors and invade surrounding tissues and other parts of the body.
  • This new copay assistance program provides the opportunity to help individuals living with Breast Cancer take charge of their treatment without the added stress of making difficult financial decisions.
  • The Assistance Fund is an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles and other health-related expenses.

New HealthWell Foundation Fund Offers Financial Assistance to Patients Living with Congenital Sucrase-Isomaltase Deficiency (CSID)

Retrieved on: 
Tuesday, November 27, 2018
CSID, Sucrase, Sucrose intolerance, Sucrose alpha-glucosidase, Maltase, Isomaltase, Lifeline, Copayment, Sacrosidase

GERMANTOWN, Md., Nov. 27, 2018 /PRNewswire/ --The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has launched a new fund to provide assistance to patients who are living with congenital sucrase-isomaltase deficiency (CSID).

Key Points: 
  • GERMANTOWN, Md., Nov. 27, 2018 /PRNewswire/ --The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has launched a new fund to provide assistance to patients who are living with congenital sucrase-isomaltase deficiency (CSID).
  • Through the fund, HealthWell will provide up to $10,000 in copayment or premium assistance to eligible patients living with CSID who have annual household incomes up to 500% of the federal poverty level.
  • This fund from HealthWell Foundation will help liftsome of that burden and givefamilies greater access to neededtreatments."
  • "People living with CSID can endure a multitude of uncomfortable, and more often, painful symptoms," commented Krista Zodet, HealthWell Foundation President.

Decision Resources Group Launches CoPay Accumulator Product Providing Health Companies With Comprehensive CoPay Benefit Insights

Retrieved on: 
Tuesday, November 6, 2018
Health insurance, Economy, Healthcare in the United States, Copayment, Accumulator, Analytics, Computing, Data

BURLINGTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Decision Resources Group (DRG) a premier provider of high-value healthcare data, analytics and insights products and services, is pleased to introduce CoPay Accumulator Threat Assessor as its latest product offering.

Key Points: 
  • BURLINGTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Decision Resources Group (DRG) a premier provider of high-value healthcare data, analytics and insights products and services, is pleased to introduce CoPay Accumulator Threat Assessor as its latest product offering.
  • DRG's CoPay Assessor combines real-world claims data, lives information, and market research to provide the most comprehensive copay accumulator database available, in an easy-to-use dashboard.
  • It offers deep analysis on copay benefit design to help pharmaceutical companies understand business impact, informing copay program strategy to help support better program outcomes.
  • "Companies are rethinking how copay programs are structured now that CoPay accumulator benefit designs no longer allow pharma coupon assistance to be applied toward patient deductibles," says Tyler Dinwiddie, Market Access Insights Senior Analyst, Decision Resources Group.

Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price

Retrieved on: 
Wednesday, October 24, 2018
Health, Healthcare reform in the United States, Medicare Australia, Federal assistance in the United States, Liberalism in the United States, Medicare, Amgen, Copayment, Evolocumab, Government

This 60 percent reduction from the medicine's original list price will improve affordability by lowering patient copays, especially for Medicare patients.

Key Points: 
  • This 60 percent reduction from the medicine's original list price will improve affordability by lowering patient copays, especially for Medicare patients.
  • No price increases on any Amgen medicines have been taken since then or are planned for the balance of the year.
  • Amgen is making Repatha available at a reduced list price by introducing new National Drug Codes (NDCs).
  • To allow for a smooth transition to these lower-priced options, Amgen will continue offering Repatha at its original list price for a period of time, with an expectation of discontinuing the original list price of Repatha by the end of 2020 or sooner.